Merck & Co., Inc. (ETR: 6MK)
107.20
-0.40 (-0.37%)
Sep 6, 2024, 5:35 PM CET
Merck & Co. Employees
As of December 31, 2023, Merck & Co. had 72,000 total employees, including 70,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.35% compared to the previous year.
Employees
72,000
Change (1Y)
3,000
Growth (1Y)
4.35%
Revenue / Employee
€821,304
Profits / Employee
€180,561
Market Cap
271.14B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Apple Inc. | 161,000 |
The Coca-Cola Company | 79,100 |
SAP SE | 107,602 |
Deutsche Telekom AG | 199,652 |
Allianz SE | 157,883 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 42,812 |
Dr. Ing. h.c. F. Porsche AG | 42,140 |
Mercedes-Benz Group AG | 166,056 |
Merck & Co. News
- 6 hours ago - Eighty-eight Corporate Leaders Endorse Harris For Continued 'Strength' Of Democracy, Economy - IBTimes
- 8 hours ago - Why Did Merck Stock Rise 65%? - Forbes
- 1 day ago - What's Going On With Merck Shares Thursday? - Benzinga
- 1 day ago - What's Wrong With Merck's Stock? - The Motley Fool
- 2 days ago - Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 - Wallstreet:Online
- 2 days ago - Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 - Business Wire
- 2 days ago - Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret for the Treatment of Diabetic Macular Edema - Wallstreet:Online
- 2 days ago - Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema - Business Wire